TOX2

Across TCGA pan-cancer cohorts, TOX2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TOX2 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher TOX2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TOX2 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

GBM, LUAD, and LSCC are the cancer types where TOX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.603	0.293	.006	11	view →
LUAD	DFS	Median	All	0.764	0.527	.047	2	view →
LSCC	OS	Median	All	0.916	0.835	.018	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TOX2–GBM (DFS)

Open the GBM breakdown →